Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
JERSEY CITY, N.J., Aug. 31, 2017 -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following upcoming investor conferences:
- Baird’s 2017 Global Healthcare Conference at the InterContinental New York Barclay Hotel on Thursday, September 7, 2017 at 8:30 a.m. ET.
- The Rodman & Renshaw 19th Annual Global Investment Conference at the Lotte New York Palace Hotel on Monday, September 11, 2017 at 9:35 a.m. ET.
- The Cantor Fitzgerald 2017 Global Healthcare Conference at the InterContinental New York Barclay Hotel on Wednesday, September 27, 2017 at 11:30 a.m. ET.
Live webcasts of each presentation will be available on the investors section of the Company’s website: www.SCYNEXIS.com. Replays of each presentation will be available approximately two hours after each event and will be available for two weeks following each presentation.
About SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is the first representative of a novel intravenous and oral triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Cammy Duong MacDougall Biomedical Communications Tel: 781-591-3443 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
